Leap Therapeutics Ownership

Leap Therapeutics maintains a total of 38.32 Million outstanding shares. 30% of Leap Therapeutics outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Leap Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Leap Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Dividends Paid is likely to drop to about 242.7 K in 2024. Dividend Yield is likely to drop to 0 in 2024. Common Stock Shares Outstanding is likely to rise to about 21.5 M in 2024, despite the fact that Net Loss is likely to grow to (46.7 M). Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Leap Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.